Literature DB >> 2778490

Sensitivity of glioma and fetal brain cell lines to natural killer cytolysis in a monolayer assay.

R M Kazimer1, R L Whisler, R E Stephens, D K Pearl, A J Yates.   

Abstract

We have developed an in vitro assay for Natural Killer (NK) cell cytolysis of and binding to substrate attached human glioma and fetal brain cells. The monolayer cells were labeled with [51Cr] and the effectors were directly sedimented onto these substrate attached target cells. Using this method we screened several glioma and fetal brain cell lines. The results indicate that the majority of gliomas are NK resistant, however two of the tested lines (U251MG and BN3) were relatively sensitive as were the fetal brain cell lines (CHI and CHII). We conclude that this monolayer assay for NK cytotoxicity and binding of glioma targets is a reproducible and valid method for assessing NK sensitivity, and should have applications in the study of other cultured solid tumors and substrate attached cells.

Entities:  

Mesh:

Year:  1989        PMID: 2778490     DOI: 10.1007/BF00165099

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors.

Authors:  J H Deck; L F Eng; J Bigbee; S M Woodcock
Journal:  Acta Neuropathol       Date:  1978-06-30       Impact factor: 17.088

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Tumor cell differentiation modulates susceptibility to natural killer cells.

Authors:  J Werkmeister; S L Helfand; T Haliotis; P Rubin; H Pross; J Roder
Journal:  Cell Immunol       Date:  1982-05-01       Impact factor: 4.868

4.  NK and K cell characteristics of human lymphocytes enriched for subpopulations isolated from NK tumor cell conjugates.

Authors:  E M Opremcak; K Bakenhaster; R L Whisler
Journal:  Cell Immunol       Date:  1981-03-01       Impact factor: 4.868

5.  Natural killer cells kill tumour cells at a given stage of differentiation.

Authors:  M Gidlund; A Orn; P K Pattengale; M Jansson; H Wigzell; K Nilsson
Journal:  Nature       Date:  1981-08-27       Impact factor: 49.962

6.  Isolation of human NK cells by density gradient centrifugation.

Authors:  T Timonen; E Saksela
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Immunohistological study of mononuclear cell infiltrate in malignant gliomas.

Authors:  M L Rossi; J T Hughes; M M Esiri; H B Coakham; D B Brownell
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

8.  Natural cytotoxic cells from rat liver and spleen kill human glioma cells.

Authors:  M Malter; R Süss; H Fischer
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

9.  Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies.

Authors:  R I von Hanwehr; F M Hofman; C R Taylor; M L Apuzzo
Journal:  J Neurosurg       Date:  1984-06       Impact factor: 5.115

10.  K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis.

Authors:  M C Dokhelar; D Garson; H Wakasugi; A Tabilio; U Testa; W Vainchenker; T Tursz
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

View more
  2 in total

1.  Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women.

Authors:  W B Malarkey; M Burleson; J T Cacioppo; K Poehlmann; R Glaser; J K Kiecolt-Glaser
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

2.  Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression.

Authors:  A M Donson; N K Foreman
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.